ADMA Relative Valuation
ADMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADMA is overvalued; if below, it's undervalued.
Historical Valuation
ADMA Biologics Inc (ADMA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.41. The fair price of ADMA Biologics Inc (ADMA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：20.11
Fair
23.94
PE
1Y
3Y
5Y
Trailing
Forward
14.28
EV/EBITDA
ADMA Biologics Inc. (ADMA) has a current EV/EBITDA of 14.28. The 5-year average EV/EBITDA is 10.23. The thresholds are as follows: Strongly Undervalued below -8.69, Undervalued between -8.69 and 0.77, Fairly Valued between 19.69 and 0.77, Overvalued between 19.69 and 29.15, and Strongly Overvalued above 29.15. The current Forward EV/EBITDA of 14.28 falls within the Historic Trend Line -Fairly Valued range.
17.42
EV/EBIT
ADMA Biologics Inc. (ADMA) has a current EV/EBIT of 17.42. The 5-year average EV/EBIT is 12.43. The thresholds are as follows: Strongly Undervalued below -40.72, Undervalued between -40.72 and -14.14, Fairly Valued between 39.00 and -14.14, Overvalued between 39.00 and 65.58, and Strongly Overvalued above 65.58. The current Forward EV/EBIT of 17.42 falls within the Historic Trend Line -Fairly Valued range.
7.80
PS
ADMA Biologics Inc. (ADMA) has a current PS of 7.80. The 5-year average PS is 4.45. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and 1.85, Fairly Valued between 7.05 and 1.85, Overvalued between 7.05 and 9.65, and Strongly Overvalued above 9.65. The current Forward PS of 7.80 falls within the Overvalued range.
20.70
P/OCF
ADMA Biologics Inc. (ADMA) has a current P/OCF of 20.70. The 5-year average P/OCF is 10.06. The thresholds are as follows: Strongly Undervalued below -64.68, Undervalued between -64.68 and -27.31, Fairly Valued between 47.44 and -27.31, Overvalued between 47.44 and 84.81, and Strongly Overvalued above 84.81. The current Forward P/OCF of 20.70 falls within the Historic Trend Line -Fairly Valued range.
32.81
P/FCF
ADMA Biologics Inc. (ADMA) has a current P/FCF of 32.81. The 5-year average P/FCF is 0.19. The thresholds are as follows: Strongly Undervalued below -216.37, Undervalued between -216.37 and -108.09, Fairly Valued between 108.47 and -108.09, Overvalued between 108.47 and 216.75, and Strongly Overvalued above 216.75. The current Forward P/FCF of 32.81 falls within the Historic Trend Line -Fairly Valued range.
ADMA Biologics Inc (ADMA) has a current Price-to-Book (P/B) ratio of 11.12. Compared to its 3-year average P/B ratio of 10.65 , the current P/B ratio is approximately 4.39% higher. Relative to its 5-year average P/B ratio of 7.47, the current P/B ratio is about 48.73% higher. ADMA Biologics Inc (ADMA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -19.09% , the current FCF yield is about -100.00% lower.
11.12
P/B
Median3y
10.65
Median5y
7.47
0.87
FCF Yield
Median3y
-1.59
Median5y
-19.09
Competitors Valuation Multiple
The average P/S ratio for ADMA's competitors is 0.00, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 12.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADMA increased by 17.26% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 20.49 to 23.49.
The secondary factor is the Revenue Growth, contributed 12.00%to the performance.
Overall, the performance of ADMA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is ADMA Biologics Inc (ADMA) currently overvalued or undervalued?
What is ADMA Biologics Inc (ADMA) fair value?
How does ADMA's valuation metrics compare to the industry average?
What is the current P/B ratio for ADMA Biologics Inc (ADMA) as of Dec 05 2025?
What is the current FCF Yield for ADMA Biologics Inc (ADMA) as of Dec 05 2025?
What is the current Forward P/E ratio for ADMA Biologics Inc (ADMA) as of Dec 05 2025?